Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
Most peptides are given as subcutaneous injections into fatty tissue, commonly the lower abdomen (roughly two inches away from the navel), the outer thigh, the upper outer buttock, or the back of the upper arm, while a few formulations are designed for intramuscular use, and rotating sites helps prevent tissue damage. Reported risks include pain, redness, swelling, bruising, itching, or lumps at the injection site, plus infection, abscess, scarring, fat tissue changes, and accidental injury to nerves or blood vessels. More serious concerns involve allergic reactions, fluid retention, joint pain, blood sugar shifts, hormonal disruption, and unknown long-term effects, and risks rise sharply with unregulated "research-grade" or compounded products that may be contaminated or incorrectly dosed. Injection site selection, needle length, dosing, and your personal health history all change how safe this is for you, and several important factors are explained below. See below to understand more before you inject anything.
If you are noticing symptoms you cannot explain, whether that is swelling, a painful injection site, unusual fatigue, or something that simply feels off, guessing is the slowest and riskiest path forward. A free, instant, online symptom check takes only a few minutes, asks the kinds of questions a clinician would ask, and helps you sort what is likely harmless from what deserves prompt attention. It gives you clear language and a starting point for your next conversation with a medical professional, so you walk in informed rather than uncertain. Understanding what is going on now is far easier than managing a complication later.
Last reviewed for medical accuracy: 09/26/2026
Where to Inject Peptides—and What the Risks Are
Peptides are short chains of amino acids that can act as hormones, growth factors or signaling molecules. They’re used in medical treatments (e.g. insulin, glucagon-like peptide-1 analogues) and in research or performance contexts (e.g. growth hormone-releasing peptides). Choosing the right injection site and using proper technique helps maximize effectiveness and minimize complications.
Most peptides given outside hospital settings are injected subcutaneously. Intramuscular or intravenous routes are reserved for specific agents and require professional training.
Subcutaneous injections go into the fatty layer just below the skin. Rotating sites prevents tissue damage. Common areas include:
Tips for subcutaneous injections:
Intramuscular (IM) injections deliver peptides into muscle tissue, where blood flow is richer and absorption faster. IM injections should only be done by trained personnel. Sites include:
IV peptide administration is uncommon outside hospital or research settings. It requires:
All injections carry some risk. Understanding and mitigating these is key.
Local Skin Reactions
Infection
Allergic or Hypersensitivity Reactions
Nerve Injury (mostly with IM injections)
Dosage Errors
Poor Absorption
• Always read and follow the manufacturer’s instructions.
• Store peptides as directed (often refrigerated) to preserve stability.
• Inspect the solution: it should be clear and free of particles.
• Prime insulin-style pens or flush IV lines as instructed to ensure accurate dosing.
• Keep a log of injection sites to ensure rotation.
• Use the shortest, smallest-gauge needle that allows proper delivery.
If you experience any of the following after peptide injection, seek medical attention promptly:
For a free, online symptom check, using the doctor approved Ubie Symptom Checker, visit UbieHealth.com.
Injecting peptides can be straightforward when you use proper technique and hygiene. By choosing the right site, rotating injections and recognizing warning signs, you greatly reduce the risk of complications.
Always talk with your healthcare provider before starting any peptide regimen. If you encounter serious side effects or anything life-threatening, stop the injections and speak to a doctor right away.
(References)
* Cheung LK, Eaton A. Age-related macular degeneration. Pharmacotherapy. 2013 Aug;33(8):838-55. doi: 10.1002/phar.1264. Epub 2013 Apr 11. PMID: 23580402.
* Breznik V, Kokol R, Luzar B, Miljković J. Insulin-induced localized lipoatrophy. Acta Dermatovenerol Alp Pannonica Adriat. 2013 Dec;22(4):83-5. PMID: 24336944.
* Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J. Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. Eur J Ophthalmol. 2020 Jan;30(1):66-71. doi: 10.1177/1120672118823128. Epub 2019 Jan 8. PMID: 30618282.
* Redler LH, Dennis ER. Treatment of Adhesive Capsulitis of the Shoulder. J Am Acad Orthop Surg. 2019 Jun 15;27(12):e544-e554. doi: 10.5435/JAAOS-D-17-00606. PMID: 30632986.
* Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology. 2021 Mar;128(3):417-424. doi: 10.1016/j.ophtha.2020.07.062. Epub 2020 Aug 8. PMID: 32781110.
* Massenzio E, Xu D, Abishek R, Wibbelsman TD, Sheng Y, Obeid A, Bhatt S, Zhang Q, Sharpe J, Park CH, Spirn MJ, Gupta OP, Chiang A, Shukla A, Shalaby WS, Myers JS, Hsu J. RISK FACTORS FOR SURGERY OR BLINDNESS IN NEOVASCULAR GLAUCOMA EYES TREATED WITH ANTI-VEGF INJECTIONS BY A RETINA SPECIALIST. Retina. 2023 Jul 1;43(7):1150-1159. doi: 10.1097/IAE.0000000000003780. PMID: 36913629.
* Milani AE, Arasteh A, Saeedi-Maleki Z, Niyousha MR, Sahebazamani MA, Brumandpur F. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection. BMC Ophthalmol. 2024 Jun 21;24(1):265. doi: 10.1186/s12886-024-03528-0. Epub 2024 Jun 21. PMID: 38907228; PMCID: PMC11191159.
* Zhao CS, Chwialkowski K, Wai KM, Mruthyunjaya P, Rahimy E, Koo EB. Risk of Cataract Surgery Complications in Patients With Prior Intravitreal Injection Therapy. Am J Ophthalmol. 2025 Apr;272:106-116. doi: 10.1016/j.ajo.2025.01.004. Epub 2025 Jan 16. PMID: 39826858.
* Almosa A, Alshaikhsalama AM, Abdi A, Alsoudi AF, Yuan M, Loya A, Rahimy E, Mahmoud TH. Association Between Retinal Vein Occlusion and Epiretinal Membrane Development. Am J Ophthalmol. 2026 Jun;286:108-122. doi: 10.1016/j.ajo.2026.02.030. Epub 2026 Feb 24. PMID: 41748056.
* Thottarath S, Gurudas S, Kubravi S, Kazantzis D, Keskin AM, Sivaprasad S, EYENEON Study Group. Nonexudative Macular Neovascularization in Age-Related Macular Degeneration. JAMA Ophthalmol. 2026 May 1;144(5):405-413. doi: 10.1001/jamaophthalmol.2026.0459. PMID: 41954906; PMCID: PMC13067133.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.